[Role of bortezomib in the treatment of multiple myeloma].
The proteasome inhibitor bortezomib is approved for the treatment of patients with relapsed/refractory multiple myeloma. Botezomib represents a new generation of treatments for multiple myeloma that affects both specific intracellular signaling pathways and the tumor microenvironment. There is a growing body of clinical evidence showing its effectiveness alone and in combination not only in relapsed/refractory cases but also in the front line setting. Regimens incorporating bortezomib and other novel agents such as immunomodulatory derivatives of thalidomide together with commonly used conventional drugs show considerable high response rates including complete response that resulting in improving survival, with or without following stem cell transplantation. Thus these approaches represent a promising future direction in myeloma treatment.
Gotoh
Akihiko
A
First Department of Internal Medicine (Department of Hematology), Tokyo Medical University.
Ohyashiki
Kazuma
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage / Q000494:pharmacology; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008081:Liposomes; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000209:etiology; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000502:physiology; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000008:administration & dosage / Q000494:pharmacology; D013792:Thalidomide / Q000008:administration & dosage
D001897:Boronic Acids; D008081:Liposomes; D016328:NF-kappa B; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D004317:Doxorubicin; D008558:Melphalan